<DOC>
	<DOCNO>NCT01675440</DOCNO>
	<brief_summary>To evaluate safety efficacy Medtronic CoreValve® System treatment symptomatic severe aortic stenosis subject significant comorbidities risk surgical aortic valve replacement predict operative mortality serious , irreversible morbidity risk ≥50 % 30 day .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Medtronic CoreValve® System-Treatment Symptomatic Severe Aortic Stenosis With Significant Comorbidities Extreme Risk Subjects Who Need Aortic Valve Replacement</brief_title>
	<detailed_description>The primary objective study evaluate safety effectiveness Medtronic CoreValve® System ( MCS ) subset subject exclude U.S . Extreme Risk Pivotal Trial population due one additional co-morbidities , measure composite all-cause death major stroke 12 month , treatment symptomatic severe aortic stenosis subject necessitate aortic valve replacement . Subjects enrol study predict operative mortality serious , irreversible morbidity risk ≥50 % 30 day associate surgical aortic valve replacement .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Subject must comorbidities one cardiologist two cardiac surgeon agree medical factor preclude operation , base conclusion probability death serious morbidity exceed probability meaningful improvement . Specifically , predict operative risk death serious , irreversible morbidity ≥ 50 % 30 day . Subjects must meet criterion least one subgroups 2ac : a. Senile degenerative aortic valve stenosis . At least one follow comorbid condition : 1 . Severe ( ≥34+ ) mitral valve regurgitation measure echocardiography 2 . Severe ( ≥34+ ) tricuspid valve regurgitation measure echocardiography 3 . Endstage renal disease require renal replacement therapy ( Stage 5 KDOQI CKD Classification ) creatinine clearance &lt; 20cc/min require renal replacement therapy AND ii . mean gradient &gt; 40 mmHg jet velocity great 4.0 m/sec either rest dobutamine stress echocardiogram ( LVEF &lt; 50 % ) , simultaneous pressure recording cardiac catheterization either rest dobutamine stress ( LVEF &lt; 50 % ) AND iii . initial aortic valve area ≤ 0.8 cm2 ( aortic valve area index ≤0.5 cm2/m2 ) rest echocardiogram simultaneous pressure recording cardiac catheterization AND/OR b . Low gradient , low output aortic stenosis define presence three follow . In presence LVEF &lt; 50 % , absence contractile reserve , mean gradient ≥25mmHg &lt; 40mmHg AND jet velocity le 4.0m/sec dobutamine stress echocardiography simultaneous pressure recording cardiac catheterization OR In presence LVEF ≥50 % , mean gradient ≥25mmHg &lt; 40mmHg AND jet velocity le 4.0 m/sec , echocardiography simultaneous pressure recording cardiac catheterization AND ii . initial aortic valve area ≤0.8 cm2 ( aortic valve area index ≤0.5 cm2/m2 ) rest echocardiogram simultaneous pressure recording cardiac catheterization AND iii . radiographic evidence severe aortic valve calcification AND/OR c. Failed bioprosthetic surgical aortic valve Subject symptomatic his/her aortic valve stenosis , demonstrate New York Heart Association ( NYHA ) Functional Class II great . The subject subject 's legal representative inform nature study , agree provision provide write informed consent approve IRB respective clinical site . The subject treating physician agree subject return require postprocedure followup visit . Clinical Evidence acute myocardial infarction ≤30 day MCS TAVI procedure . Any percutaneous coronary peripheral interventional procedure perform within 30 day prior MCS TAVI procedure Blood dyscrasia define : leukopenia ( WBC &lt; 1000mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy . Untreated clinically significant coronary artery disease require revascularization . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . Need emergency surgery reason . Severe ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % measure rest echocardiogram . Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . Active Gastrointestinal ( GI ) bleed would preclude anticoagulation . A known hypersensitivity contraindication anticoagulation/antiplatelet regimen ( include ability anticoagulated index procedure ) , nitinol , [ allergic ] sensitivity contrast medium adequately premedicated . Ongoing sepsis , include active endocarditis . Subject refuse blood transfusion . Life expectancy &lt; 12 month due associate noncardiac comorbid condition . Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent . Severe dementia ( result either inability provide inform consent study/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . Currently participate investigational drug another device study . Symptomatic carotid vertebral artery disease . Anatomical Subject : Native aortic annulus size &lt; 18 mm &gt; 29 mm per baseline diagnostic imaging ( applicable TAV SAV subject ) OR Surgical bioprosthetic annulus &lt; 17mm &gt; 29mm i. Stented SAV per manufacture labeled inner diameter OR ii . Stentless SAV per baseline diagnostic imaging Subject preexist prosthetic heart valve rigid support structure either mitral pulmonic position : 1. could affect implantation function study valve OR 2. implantation study valve could affect function preexist prosthetic heart valve Moderate severe mitral stenosis . Mixed aortic valve disease : aortic stenosis aortic regurgitation predominant aortic regurgitation , ( AR moderatesevere severe ( ≥34+ ) ) ( except fail surgical bioprothesis ) Hypertrophic obstructive cardiomyopathy . Echocardiographic evidence new untreated intracardiac mass , thrombus vegetation . Severe basal septal hypertrophy outflow gradient . Aortic root angulation ( angle plane aortic valve annulus horizontal plane/vertebrae ) &gt; 70° ( femoral leave subclavian/axillary access ) &gt; 30° ( right subclavian/axillary access ) . Ascending aorta exceeds maximum diameter give native surgical bioprosthetic* aortic annulus size ( see table ) Aortic Annulus Diameter/ Ascending Aorta Diameter , 18 mm* 20 mm/ &gt; 34 mm , 20 mm 23 mm/ &gt; 40 mm , 23 mm 27 mm/ &gt; 43 mm , 27 mm 29 mm/ &gt; 43 mm , * 17mm surgical bioprosthetic aortic annulus Congenital bicuspid unicuspid valve verify echocardiography ( Not applicable TAV SAV subject ) . Sinus valsalva anatomy would prevent adequate coronary perfusion . Degenerated surgical bioprothesis present significant concomitant perivalvular leak ( prothesis native annulus ) , securely fix native annulus , structurally intact ( e.g . wireform frame fracture ) ( ONLY FOR TAV SAV subject ) Degenerated surgical bioprothesis present partially detach leaflet aortic position may obstruct coronary ostium ( ONLY FOR TAV SAV subject ) Vascular Transarterial access able accommodate 18Fr sheath .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>